[go: up one dir, main page]

RS49504B - Antitrombični i antiaterogeni farmaceutski preparat koji obuhvata derivat tienopiridina i inhibitor hmg-coa-reduktaze - Google Patents

Antitrombični i antiaterogeni farmaceutski preparat koji obuhvata derivat tienopiridina i inhibitor hmg-coa-reduktaze

Info

Publication number
RS49504B
RS49504B YU3199A YU3199A RS49504B RS 49504 B RS49504 B RS 49504B YU 3199 A YU3199 A YU 3199A YU 3199 A YU3199 A YU 3199A RS 49504 B RS49504 B RS 49504B
Authority
RS
Serbia
Prior art keywords
hmg
pharmaceutical composition
coa reductase
reductase inhibitor
antithrombotic
Prior art date
Application number
YU3199A
Other languages
English (en)
Inventor
Georges Daste
Jean-Marc Herbert
Original Assignee
Sanofi-Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Synthelabo filed Critical Sanofi-Synthelabo
Publication of YU3199A publication Critical patent/YU3199A/sh
Publication of RS49504B publication Critical patent/RS49504B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
    • F16K—VALVES; TAPS; COCKS; ACTUATING-FLOATS; DEVICES FOR VENTING OR AERATING
    • F16K41/00—Spindle sealings
    • F16K41/02—Spindle sealings with stuffing-box ; Sealing rings
    • F16K41/04—Spindle sealings with stuffing-box ; Sealing rings with at least one ring of rubber or like material between spindle and housing
    • F16K41/043—Spindle sealings with stuffing-box ; Sealing rings with at least one ring of rubber or like material between spindle and housing for spindles which only rotate, i.e. non-rising spindles
    • F16K41/046—Spindle sealings with stuffing-box ; Sealing rings with at least one ring of rubber or like material between spindle and housing for spindles which only rotate, i.e. non-rising spindles for rotating valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F02—COMBUSTION ENGINES; HOT-GAS OR COMBUSTION-PRODUCT ENGINE PLANTS
    • F02D—CONTROLLING COMBUSTION ENGINES
    • F02D9/00—Controlling engines by throttling air or fuel-and-air induction conduits or exhaust conduits
    • F02D9/04—Controlling engines by throttling air or fuel-and-air induction conduits or exhaust conduits concerning exhaust conduits
    • F02D9/06—Exhaust brakes
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
    • F16K—VALVES; TAPS; COCKS; ACTUATING-FLOATS; DEVICES FOR VENTING OR AERATING
    • F16K1/00—Lift valves or globe valves, i.e. cut-off apparatus with closure members having at least a component of their opening and closing motion perpendicular to the closing faces
    • F16K1/16—Lift valves or globe valves, i.e. cut-off apparatus with closure members having at least a component of their opening and closing motion perpendicular to the closing faces with pivoted closure-members
    • F16K1/18—Lift valves or globe valves, i.e. cut-off apparatus with closure members having at least a component of their opening and closing motion perpendicular to the closing faces with pivoted closure-members with pivoted discs or flaps
    • F16K1/22—Lift valves or globe valves, i.e. cut-off apparatus with closure members having at least a component of their opening and closing motion perpendicular to the closing faces with pivoted closure-members with pivoted discs or flaps with axis of rotation crossing the valve member, e.g. butterfly valves

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mechanical Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Combustion & Propulsion (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Farmaceutski preparat koji sadrži a) derivat tienopiridina formule: u kojoj je R, vodonik ili grupa (C1-C4)alkoksikarbonil ili njegove farmaceutski prihvatljive soli, i b) inhibitor HMG-CoA-reduktaze. U količini dovoljnoj da obezbedi poboljšanje antiaterogene i/ili antitrombične aktivnosti. Prijava sadrži još 2 nezavisna i 11 zavisnih patentnih zahteva.
YU3199A 1996-07-26 1997-07-21 Antitrombični i antiaterogeni farmaceutski preparat koji obuhvata derivat tienopiridina i inhibitor hmg-coa-reduktaze RS49504B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9609474A FR2751540B1 (fr) 1996-07-26 1996-07-26 Composition pharmaceutique antithrombotique
PCT/FR1997/001353 WO1998004259A1 (fr) 1996-07-26 1997-07-21 COMPOSITION PHARMACEUTIQUE ANTITHROMBOTIQUE ET ANTIATHEROGENE COMPRENANT UN DERIVE DE THIENOPYRIDINE ET UN INHIBITEUR DE LA HMG-CoA-REDUCTASE

Publications (2)

Publication Number Publication Date
YU3199A YU3199A (sh) 2002-09-19
RS49504B true RS49504B (sr) 2006-10-27

Family

ID=9494551

Family Applications (1)

Application Number Title Priority Date Filing Date
YU3199A RS49504B (sr) 1996-07-26 1997-07-21 Antitrombični i antiaterogeni farmaceutski preparat koji obuhvata derivat tienopiridina i inhibitor hmg-coa-reduktaze

Country Status (35)

Country Link
US (1) US6218403B1 (sr)
EP (1) EP0914124B1 (sr)
JP (1) JP3553610B2 (sr)
KR (1) KR100307268B1 (sr)
CN (1) CN1109547C (sr)
AR (1) AR008782A1 (sr)
AT (1) ATE258052T1 (sr)
AU (1) AU725949B2 (sr)
BR (1) BR9710560B1 (sr)
CA (1) CA2261099C (sr)
CZ (1) CZ294664B6 (sr)
DE (1) DE69727299T2 (sr)
DK (1) DK0914124T3 (sr)
EE (1) EE03853B1 (sr)
ES (1) ES2214632T3 (sr)
FR (1) FR2751540B1 (sr)
HK (1) HK1019405A1 (sr)
HU (1) HU226245B1 (sr)
ID (1) ID17774A (sr)
IL (1) IL128102A0 (sr)
IS (1) IS2052B (sr)
MY (1) MY125051A (sr)
NO (1) NO322894B1 (sr)
NZ (1) NZ333826A (sr)
PL (1) PL188739B1 (sr)
PT (1) PT914124E (sr)
RS (1) RS49504B (sr)
RU (1) RU2176504C2 (sr)
SI (1) SI0914124T1 (sr)
SK (1) SK284944B6 (sr)
TR (1) TR199900154T2 (sr)
TW (1) TW442289B (sr)
UA (1) UA58518C2 (sr)
WO (1) WO1998004259A1 (sr)
ZA (1) ZA976247B (sr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2769313B1 (fr) * 1997-10-06 2000-04-21 Sanofi Sa Derives d'esters hydroxyacetiques, leur procede de preparation et leur utilisation comme intermediaires de synthese
US7141602B2 (en) * 1998-09-18 2006-11-28 Lek Pharmaceuticals D.D. Process for obtaining HMG-CoA reductase inhibitors of high purity
CN1620293A (zh) * 2001-12-18 2005-05-25 特瓦制药工业有限公司 氯吡格雷硫酸氢盐的多晶型
US7074928B2 (en) 2002-01-11 2006-07-11 Teva Pharmaceutical Industries, Ltd. Polymorphs of clopidogrel hydrogensulfate
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
IL166593A0 (en) 2002-08-02 2006-01-15 Racemization and enantiomer separation of clopidogrel
US6800759B2 (en) 2002-08-02 2004-10-05 Teva Pharmaceutical Industries Ltd. Racemization and enantiomer separation of clopidogrel
WO2004110427A1 (en) * 2003-06-18 2004-12-23 Institut De Cardiologie De Montréal /Montréal Heart Institute Preventing atrial fibrillation (af) with the use of statin drugs
US6978908B2 (en) * 2003-09-15 2005-12-27 Gerber Products Company Drinking vessel with adjustable handles
KR100563455B1 (ko) * 2004-04-09 2006-03-23 한미약품 주식회사 결정성 클로피도그렐 나프탈렌술폰산염 또는 이의 수화물,이의 제조방법 및 이를 함유하는 약학적 조성물
KR101299320B1 (ko) * 2005-09-15 2013-09-03 오츠카 세이야쿠 가부시키가이샤 초과산화물 억제제 효과를 갖는 프로부콜 및테트라졸릴알콕시-디히드로카르보스티릴 유도체를 함유하는조합 약물
US9532945B2 (en) * 2006-04-04 2017-01-03 Kg Acquisition Llc Oral dosage forms including an antiplatelet agent and an enterically coated acid inhibitor
LT2007362T (lt) * 2006-04-04 2018-11-26 Kg Acquisition Llc Geriamosios vaisto formos, apimančios prieštrombocitinį agentą ir rūgšties inhibitorių
TW200825093A (en) * 2006-08-03 2008-06-16 Teva Pharma Process for preparing clopidogrel bisulphate
WO2008060934A2 (en) * 2006-11-14 2008-05-22 Acusphere, Inc. Formulations of tetrahydropyridine antiplatelet agents for parenteral or oral administration
BRPI0810168A2 (pt) * 2007-04-09 2014-12-30 Usv Ltd Composições farmacêuticas de bissulfato de clopidogrel e processos de preparação das mesmas
WO2008129468A2 (en) * 2007-04-20 2008-10-30 Wockhardt Research Centre Pharmaceutical compositions of clopidogrel
CN104800210B (zh) * 2007-04-27 2019-08-06 锡德克斯药物公司 包含氯吡格雷和磺基烷基醚环糊精的制剂和其使用方法
WO2010009745A1 (en) * 2008-07-25 2010-01-28 Pharmathen S.A. Solid oral dosage form containing anti-platelet agent clopidogrel and method for the preparation thereof
JP5706409B2 (ja) 2009-06-25 2015-04-22 テトラ，エスイーアー 新規なサリチル酸塩
RU2461379C2 (ru) * 2010-12-09 2012-09-20 Закрытое акционерное общество "ФАРМ-ЦЕНТР" (ЗАО "ФАРМ-ЦЕНТР") Фармацевтическая комбинация, обладающая антиагрегантной и липидрегулирующей активностями, фармацевтическая композиция
EP3572075A2 (en) 2017-01-23 2019-11-27 Dong Wha Pharm. Co., Ltd. Complex formulation comprising hmg-coa reductase inhibitor and clopidogrel

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2003478A1 (en) * 1988-12-12 1990-06-12 Leonard G. Dennick Combination of an hmg coa reductase inhibitor and other type of serum cholesterol reducing agent and method for lowering serum cholesterol using such combination
FR2665440B1 (fr) * 1990-07-31 1994-02-04 Lipha Nouveaux cycloalkylsulfonamides substitues, procedes de preparation et medicaments les contenant.
WO1995011898A1 (en) * 1992-05-12 1995-05-04 Nissan Chemical Industries Ltd. Condensed pyridine type mevalonolactone intermediate and process for its production
WO1995013063A1 (en) * 1993-11-09 1995-05-18 Merck & Co., Inc. HMG-CoA REDUCTASE INHIBITORS IN THE NORMALIZATION OF VASCULAR ENDOTHELIAL DYSFUNCTION
US5945432A (en) * 1995-12-22 1999-08-31 The University Of Vermont And State Agricultural College Thrombolytic agents and thienopyridine derivatives in acute stroke

Also Published As

Publication number Publication date
IS2052B (is) 2005-10-14
TR199900154T2 (xx) 1999-04-21
ID17774A (id) 1998-01-29
US6218403B1 (en) 2001-04-17
MY125051A (en) 2006-07-31
YU3199A (sh) 2002-09-19
CA2261099C (fr) 2003-04-15
IS4951A (is) 1999-01-22
PT914124E (pt) 2004-05-31
SI0914124T1 (en) 2004-06-30
NO990321D0 (no) 1999-01-25
IL128102A0 (en) 1999-11-30
BR9710560B1 (pt) 2013-12-03
ES2214632T3 (es) 2004-09-16
NO990321L (no) 1999-03-22
CN1109547C (zh) 2003-05-28
RU2176504C2 (ru) 2001-12-10
AR008782A1 (es) 2000-02-23
NO322894B1 (no) 2006-12-18
ATE258052T1 (de) 2004-02-15
TW442289B (en) 2001-06-23
DK0914124T3 (da) 2004-05-17
DE69727299T2 (de) 2004-10-21
NZ333826A (en) 2000-09-29
SK7899A3 (en) 1999-07-12
EE9900028A (et) 1999-08-16
HU226245B1 (en) 2008-07-28
AU3852697A (en) 1998-02-20
PL188739B1 (pl) 2005-04-29
FR2751540A1 (fr) 1998-01-30
KR20000029484A (ko) 2000-05-25
JP3553610B2 (ja) 2004-08-11
DE69727299D1 (de) 2004-02-26
CZ294664B6 (cs) 2005-02-16
EE03853B1 (et) 2002-10-15
KR100307268B1 (ko) 2001-09-24
BR9710560A (pt) 1999-08-17
EP0914124A1 (fr) 1999-05-12
EP0914124B1 (fr) 2004-01-21
AU725949B2 (en) 2000-10-26
FR2751540B1 (fr) 1998-10-16
HUP9903752A2 (hu) 2000-03-28
HK1019405A1 (en) 2000-02-11
PL331339A1 (en) 1999-07-05
CZ17699A3 (cs) 1999-05-12
ZA976247B (en) 1999-01-15
WO1998004259A1 (fr) 1998-02-05
UA58518C2 (uk) 2003-08-15
SK284944B6 (sk) 2006-03-02
CA2261099A1 (fr) 1998-02-05
HUP9903752A3 (en) 2001-12-28
JP2000500781A (ja) 2000-01-25
CN1228698A (zh) 1999-09-15

Similar Documents

Publication Publication Date Title
RS49504B (sr) Antitrombični i antiaterogeni farmaceutski preparat koji obuhvata derivat tienopiridina i inhibitor hmg-coa-reduktaze
HRP20020182B1 (en) Benzamide formulation with histone deacetylase inhibitor activity
UY26082A1 (es) Derivados de 1,4-diazabiciclo [3.2.2] nonan-4-carboxilato y -carboxamidas, su preparacion y su aplicacion en terapeutica
YU69902A (sh) Novi derivati piperazina
AP2002002565A0 (en) Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases.
PT650476E (pt) Agente vasodilatador periferico que contem derivados n-acilados de 4-amino-piperidina como ingredientes activos
BR0112160A (pt) Agentes antiinflamatórios seletivos para glicocorticóides
SE9504661D0 (sv) New compounds
BR9811099A (pt) Inibidores de urocinase
WO2000000157A3 (en) Use of tempo and tempo derivatives for inducing cell death
WO2000039083A3 (en) Pyrazole compounds and uses thereof
RS49583B (sr) Karbapenem antibiotik, kompozicija i postupak za dobijanje
AU4229499A (en) Tricyclic heteroaromatics and their derivatives as inhibitors of matrix metalloproteinases
MD502G2 (ro) Derivaţi noi ai adenozinei, procedee de preparare a lor, compoziţii farmaceutice ce le conţin
AU7270798A (en) Antithrombotic agents
PT842185E (pt) Derivados da ara-c
BG102661A (en) Benzo/o/quinolysine derivatives, their preparation and application as 5a-reductase inhibitors
AU2420001A (en) Methods and compositions for the treatment of pain
YU48671B (sh) Novi derivati beta-fenilizoserina, njegovo dobijanje i primena
ES2192789T3 (es) Derivados de hidrazono-benzazuleno, composiciones farmaceuticas y compuestos intermedios.
RS50033B (sr) Derivati etansulfonil-piperidina
AU7470098A (en) Antithrombotic agents
WO2001010848A3 (en) Diazocin-dione derivatives and their use s tryptase inhibitors
AU2002239438A1 (en) 2,4-hexadienoic acid and derivatives as corrosion inhibitors
AP2002002595A0 (en) Heterocyclic amide derivatives.